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Abstract
Background: The cardiac regenerative potential of newly developed therapies is traditionally evaluated in rodent models of
surgically induced myocardial ischemia. A generally accepted key parameter for determining the success of the applied
therapy is the infarct size. Although regarded as a gold standard method for infarct size estimation in heart ischemia,
histological planimetry is time-consuming and highly variable amongst studies. The purpose of this work is to contribute
towards the standardization and simplification of infarct size assessment by providing free access to a novel semi-
automated software tool. The acronym MIQuant was attributed to this application.
Methodology/Principal Findings: Mice were subject to permanent coronary artery ligation and the size of chronic infarcts
was estimated by area and midline-length methods using manual planimetry and with MIQuant. Repeatability and
reproducibility of MIQuant scores were verified. The validation showed high correlation (r
midline length=0.981; r
area=0.970 )
and agreement (Bland-Altman analysis), free from bias for midline length and negligible bias of 1.21% to 3.72% for area
quantification. Further analysis demonstrated that MIQuant reduced by 4.5-fold the time spent on the analysis and,
importantly, MIQuant effectiveness is independent of user proficiency. The results indicate that MIQuant can be regarded as
a better alternative to manual measurement.
Conclusions: We conclude that MIQuant is a reliable and an easy-to-use software for infarct size quantification. The
widespread use of MIQuant will contribute towards the standardization of infarct size assessment across studies and,
therefore, to the systematization of the evaluation of cardiac regenerative potential of emerging therapies.
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Introduction
Cardiovascular disease is a leading cause of morbidity and
mortality worldwide. Heart failure due to ischemic coronary artery
disease is currently the most common cardiac disorder and it
correlates with a worse prognosis [1,2]. The physiological,
histological and molecular changes associated with clinical
ischemic heart disease have been clarified with the use of
experimental models of myocardial infarction (MI) developed in
both large animals, including dogs and swine, as well as in small
rodents [3,4]. The latter are more applicable for high-throughput
screening of novel therapeutic approaches, due to the easy
maintenance, short reproductive cycle and to the latest advances
in gene-targeting and transgenic technologies. In recent years, the
evaluation of cardiac regenerative potential of newly developed
therapies, as is the case of gene-delivery and transplantation
of stem/progenitor-cells, has been primarily explored in rat
and mouse models of surgically-induced myocardial ischemia
[2,5,6,7,8]. The so-called left anterior descending (LAD) coronary
artery ligation is the prominent model in these studies, and the
infarct size has been considered a key parameter for assessing the
success of the novel therapy. A strong correlation between the
infarction size and the functional and hemodynamic alterations
following myocardial infarction is generally observed [9,10,11]
and therefore considered a fundamental measure in the assessment
of the morphological and functional consequences of infarction.
In studies involving an experimental MI setting, the calculation
of the infarct size is typically evaluated by histological measure-
ments of either: (a) the endocardial and epicardial length [10,12],
(b) the midline length [10], (c) the endocardial length [9] or (d) the
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regions. Despite the widespread use of the aforementioned
approaches, the infarct size can vary depending on the used
method [10,14] and therefore no direct comparison can be
withdrawn across laboratories. Moreover, several aspects of MI
size quantification that can also account for infarct size variation
are inconsistent across studies and not always clearly defined, e.g.
the number of sections used for the calculation, the histological
staining and criteria used to identify the infarcted region. Thus, the
purpose of the present work is to contribute towards standardi-
zation and simplification of the infarct size assessment in
experimental models of MI by making available, as freeware, an
easy-to-use semi-automatic software application, which we devel-
oped and validated at the ‘‘bench’’. This tool will contribute for
the systematization of the evaluation of cardiac regenerative
potential of newly developed therapies. The acronym MIQuant that




Male and female C57BL/6 mice aged 8 to 12 weeks were used
for this study. All the procedures were subjected to approval by the
IBMC-INEB (Instituto de Biologia Molecular e Celular – Instituto
de Engenharia Biome ´dica) Animal Ethics Committee and to the
National Direc ¸a ˜o Geral de Veterina ´ria (permit no: 022793),
and are in conformity with the Directive 2010/63/EU of the
European Parliament. Humane endpoints were followed in
accordance to the Organisation for Economic Co-operation and
Development (OECD) Guidance Document on the Recognition,
Assessment, and Use of Clinical Signs as Humane Endpoints for
Experimental Animals Used in Safety Evaluation (2000).
Surgical Induction of Myocardial Infarction
MI was experimentally induced by ligation of the LAD
coronary artery as described elsewhere [13] with minor alter-
ations. Following anesthesia by intraperitoneal injection (ip) of
medetomidine (Sededorm, 1 mg/Kg) and ketamine (Clorketam,
75 mg/kg), animals were subjected to endotracheal intubation and
were mechanically ventilated using a small-animal respirator
(Minivent 845, Harvard Apparattus). Animals were maintained on
warming pads during surgical procedure and until full recovery to
prevent hypothermia. Under a stereomicroscope (Leica EZ4,
Leica Microsystems) the heart was exposed (Ø 5–7 mm) via left
thoracotomy on the third intercostal space and the pericardial sac
was gently disrupted. After identification of the LAD coronary
artery a non-absorbable 7-0 suture (SilkamH, B. Braun) was passed
under the artery and the ligation was performed. The intercostal
incision was closed by an absorbable 6-0 suture (SafilH, B. Braun)
and surgical staples were used for skin closure. Anesthesia was
reverted by atipamezole (ip, Revertor, 5 mg/Kg) and analgesia
was achieved by butorphanol (ip, Butador, 1 mg/Kg). Analgesia
and fluid therapy were performed by ip delivery of butorphanol
(Butador, 1 mg/kg) and 5% glucose physiological saline, respec-
tively. This procedure was repeated every 12 h up to 72 h post-
surgery or until full animal recovery.
For organ collection animals were deeply anesthetized by ip
injection of pentobarbital (Eutasil, 70 mg/kg). At 21days post-
surgery, hearts were harvested, briefly washed in phosphate buffer
saline and fixed in 10% Formalin neutral buffer (VWR BDH &
Prolabo) up to 24 hours prior to paraffin-embedding. The
sampling procedure herein described results on hearts arrested
at variable stages of heart cycle, which may contribute to increased
variability of infarct size. Whenever normalization is a require-
ment, hearts should be arrested in diastole following injection with
potassium chloride.
Histological procedures
Representative sampling of the LV (approx. 12 sections) was
obtained by transverse sectioning (3 mm) from the apex to the base
(atrium region) of paraffin-embedded hearts with an interval of
300 mm among each section (Figure 1A).
Paraffin sections were stained with modified Masson’s trichrome
staining (MT). MT staining was performed according to the
Trichrome (Masson) Stain kit (Sigma-Aldrich) with the following
modifications: nuclei were pre-stained with Celestine Blue solution
following staining with Gill’s Hematoxylin and incubation for
1 hour in aqueous Bouin’s solution to promote a uniform staining.
Myocardial infarct size calculation
For infarct size determination the collagen deposition, high-
lighted (blue) in MT-stained sections collected at 21 days post-
infarction, was used to define the LV scarred region. Images of
histological sections were captured with an Olympus SZX10
stereomicroscope and Olympus DP21 camera. The percentage of
affected LV wall was calculated by two different and previously
validated methods: the area measurement (calculated by dividing the
infarct area by the total LV area) [13] and the midline length
measurement (calculated by dividing the midline length of the
infarcted LV wall by the midline length of total LV wall). Only
regions with infarct in .50% of the whole thickness of the
myocardium were considered for infarct midline [10]. The MI size
determination was performed either manually, by drawing points
to outline different anatomical/pathological regions using the
Image J 1.42 software (Figure 1B), or by using MIQuant (Figure 1C).
Software design
The MIQuant software was implemented in MATLAB
TM and a
MS Windows
TM 32-bit compiled version is available online at
http://paginas.fe.up.pt/,quelhas/MIQuant/MIQuant.zip. With
the objective of developing an approach for automatic infarct size
estimation several image processing methodologies were tested
[15] and, within all tested semi-supervised methods, region
growing was found to work best and also faster, being selected
for the final software implementation.
Data and statistical analysis
To validate MIQuant, four expert researchers analyzed five
hearts (twelve sections per heart) using midline and area methods,
manually and with MIQuant. All experts repeated measures at three
distanced moments (one month between 1
st and 2
nd measure and
one week between 2
nd and 3
rd). A one-way repeated measures
analysis of variance (ANOVA) was conducted to evaluate
repeatability. Seven non-trained volunteers measured the same
samples using MIQuant. The association between manual and
MIQuant results was investigated using the Pearson product-
moment-correlation coefficient (r). Additionally, to address agree-
ment amongst methods, the Bland-Altman agreement statistical
method was used [16] following verification of the normal
distribution (Gaussian) of results. A two-way between-groups
ANOVA was applied to address the impact of observers and heart
samples in the results. Post-hoc comparison using the Tukey HSD
test was performed. Expert and volunteer results were compared
by an independent-samples t-test. The time required for manual
and MIQuant-assisted infarct size calculation was compared by the
Mann-Whitney test.
MIQuant-Semi-Automation of Infarct Size Assessment
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Software overview and availability
MIQuant is a user-friendly software application that assists on the
infarct size quantification in an experimental MI-setting. The
infarct size, defined as the percentage of the LV affected by
coronary artery occlusion, is estimated with representative cross-
sections of the LV stained with MT that enables the identification
of collagen deposition, a hallmark of established infarction. The
software allows the upload of single or multiple images and enables
the computation of the MI size of each image, calculated by area
[13] and midline length [10] methods, and the total infarct size
mean value that can be saved in excel file-format.
MIQuant was designed by applying the region growing image
segmentation method, which exploits the spatial context of pixels
with similar pixel-color properties. The main criterion for the
algorithm of region growing is homogeneity, similar pixels (or
regions) that are neighbors are joined together. For each image,
region growing requires initial image points (or seeds) that define
the region of interest. From these initial points the algorithm grows
until no more neighbors can be joined to the region of interest,
therefore regions/pixels are merged if they satisfy the chosen
Figure 1. Manual and MIQuant semi-automated calculation of MI size in chronic infarcts. (A) LV representative MT stained sections,
numbered from the apex to the LV base, were obtained from an infarcted heart harvested at 21 days post-surgery. (B) Histological infarct size
calculation by the area method requires manual tracing of the LV myocardium (light gray) and of the scarred LV tissue (black). The infarct size,
expressed as a percentage, is the division of the infarct area by the LV area multiplied by 100. For the midline length approach (right) the midline,
herein defined as the mid-region between the epicardial and endocardial surfaces, of the total LV (dashed line) and of scarred region (full line) are
manually traced. The infarct size, expressed as a percentage, is the division of the infarct midline length by the LV midline length multiplied by 100.
The total LV infarct extent is the average of infarct size obtained for the LV representative cross-sections (A). (C) Screen shot of MIQuant layout
following infarct size calculation. Multiple images can be uploaded in TIFF or JPEG file-formats and the software calculates the intermediate valueso f
infarct size for each image (bottom right). A total MI size is also generated assuming that the uploaded images were representative sections of the LV.
For selection of the scarred myocardium (top right) the software requires the user to double-click in a normal tissue region and in the LV lumen, if
applicable, over the uploaded image (top left).
doi:10.1371/journal.pone.0025045.g001
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[17,18]. In the MIQuant software the user is asked to provide input
seed points for the LV lumen (if present in the image) and the
viable myocardium (if present in the image), prior to automated
segmentation. The choice of not requiring the user to select the
infarcted LV region has to do with the heterogeneity of the
ischemic tissue. The user clicks with the mouse on the heart section
image and gives as many input points as desired. Following
selection of the viable myocardium and/or LV lumen the
segmentation is generated and displayed on the screen. This will
be the support for the infarct size computation. User adjustments
to the segmentation are accessible by varying the merging criteria
and the segmentation process can be repeated until the user is
satisfied with the results. When the segmentation is complete the
user can request computation of infarct size results by both midline
length and area methods. For the midline length measurement,
the MIQuant software automatically traces lines from the lumen
centre outwards and identifies the middle distance between tissue
boundaries. The midline of the infarcted region was considered
when the LV wall was affected in more than 50% in radial
direction. The midline generated by the software can be adjusted
by the user prior to MI size calculation.
Commands for image edition are available on the ‘‘edit menu’’,
which permits the removal of tissue regions/artifacts that may
interfere with tissue automated segmentation, e.g. the right
ventricle or blood within the LV lumen.
The MIQuant software was implemented in MATLAB
TM and a
MS Windows
TM 32 bit compiled version is available online at
http://paginas.fe.up.pt/,quelhas/MIQuant/MIQuant.zip. The
archive should be downloaded and unzipped into a specific folder.
The MIQuant manual reading is recommended prior to beginning
with the software, available at http://www.fe.up.pt/,quelhas/
MIQuant/MIQuant_manual.pdf. MIQuant requires the installa-
tion of MATLAB
TM or of the MATLAB
TM Component Runtime
(MCR) installer (http://paginas.fe.up.pt/,quelhas/MIQuant/
MCRInstaller.zip). The application can be initiated by double-
click on the executable ‘‘MIQuant’’ file. More information about
the software usage and installation is available at the MIQuant
website http://www.fe.up.pt/,quelhas/MIQuant/.
MIQuant repeatability and reproducibility
Manual and MIQuant infarct size quantification was assessed by
two well-validated methods, i.e. the area and the midline length
measurement (Figure 2A). Visual inspection of the infarct size
scores across methods demonstrate that MIQuant results are
consistent with the manual assessment, and thus infarct values
obtained with the area measurement were significantly smaller
than the midline length infarct scores. The similarity between the
manual and MIQuant approaches demonstrate that the latter might
constitute an alternative for the histological quantification of
infarct size. Further validation of MIQuant is detailed bellow.
Intra- (repeatability) and inter-observer (reproducibility) vari-
ability was considered in the experimental design, thus three
independent measures were conducted by four different users.
Repeated measures one-way ANOVA was applied to compare the
repeatability of the area and midline length-based methods, both
calculated manually and by using MIQuant. The LV infarct size
means with standard deviations and ANOVA results are detailed
in table 1. No significant effect of the repetition was found on the
infarct size obtained per section and per heart, i.e. mean value of 12
Figure 2. Consistency and reproducibility of MIQuant infarct size calculation. (A) Consistency of manual and MIQuant infarct size results
obtained using the area and midline length measurements. Hearts were harvested at 21 days post-surgery and infarct size determinations are the
mean value of 12 cross-sections representative of the LV. Mann-Whitney statistical analysis demonstrated significant differences between the area
and midline length methods, as already described by Takagawa [10]. (B) Reproducibility of MIQuant measurements. Although ANOVA demonstrated
no significant influence of the observer on the LV infarct size scores obtained, neither manually nor using MIQuant, the latter displays a tendency for
lower discrepancy between operators. e indicates the mean value of each group. * p,0.05.
doi:10.1371/journal.pone.0025045.g002
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MIQuant measurements obtained at different instances.
Inter-observer variability for each analyzed sample is displayed
on Fig. 2B. A two-way ANOVA was conducted to investigate
whether the observer influences (inter-observer variability) infarct
size measurements manually or using MIQuant. Post-hoc compar-
ison using the Tukey HSD test indicated that the mean score of
infarct size, for each heart, did not differ significantly (p.0.05)
among observers in any of the tested infarct size quantification
methods. However, a tendency for increased variability of the
manual results when compared to MIQuant was observed and was
particularly evident on heart C, which is the sample that retrieved
more deviation amongst users (Figure 2B).
Validation of MIQuant infarct size quantification
A scatter diagram of the infarct size values measured manually
and by MIQuant is shown in Fig. 3A. The Pearson Product-
moment correlation for the individual data points was r=0.981 for
the midline length and r=0.970 for the area methods, with a
significance level of p,0.01, hence the infarct size values obtained
by MIQuant are strongly associated to the manual quantification.
The strong correlation between manual and MIQuant results
prompted further analysis to evaluate the magnitude and direction
of the differences between methods.
The gold-standard statistical analysis applied to method-
comparison studies is the Bland-Altman plot, which determines
the agreement of two methods that measure the same variable
[16,19]. Manual and MIQuant results were subjected to the Bland-
Altman agreement statistical method that predicts the bias, i.e.
difference in values obtained by the two methods, and the limits of
agreement between methods (Figure 3B and C). Bias and
concordance limits of 62% and 67%, respectively, were
established a priori as the maximum parameters for acceptance of
MIQuant regarding per heart infarct size quantifications. These
values were selected on the basis of acceptance limits addressed for
infarct size methods on published studies [20,21,22,23]. The a
priori establishment of acceptable agreement limits for infarct size
per section was conditioned by the fact that, to our best knowledge,
no previous comparison was performed for single sections. Hence,
since it is expected higher degree of discordance across sections,
when compared to the mean value, a low-stringency predeter-
mined bias and concordance limits of 62% and 615%,
respectively, were established.
Bland-Altman analysis was conducted with manual and
MIQuant results obtained per LV section (Figure 3B). The estimated
bias is 0.36% with concordance limits of 210.72% and 11.45%
for the midline length method, whereas for the area approach the
bias is 2.68% with limits of agreement of 27.59% and 12.94%
(Figure 3B). Hence, for both methodological approaches, the
predicted confidence interval is within acceptance limits and so
MIQuant is considered equivalent to the established manual
quantification method.
The visual inspection of Bland-Altman plot denoted that
differences between MIQuant and manual measurements are
scattered around the bias with no obvious pattern for the midline
length results whereas, the area differences appear to increase for
higher infarction values (Figure 3B). To determine whether an
association exists between the methods discrepancies and the size
of infarction, the Pearson coefficient was calculated and a small,
non-statistically significant correlation between the two variables
was observed (r=0.063; p=0.337).
Measurements of the infarct size per heart, i.e. mean value of 12
sections representative of the LV, obtained by the manual and
MIQuant calculation were also compared accordingly to the Bland-
Altman concordance analysis. For the midline length the predicted
bias is 0.25% and the limits of agreement are 23.60% and 4.09%,
resulting on 7.74% amplitude of concordance (Figure 3C). The
analysis of the area measurements retrieves a mean difference of
2.47% (95% confidence interval (CI) from 1.21% to 3.72%),
suggesting that MIQuant tends to give a higher reading from 1.21%
to 3.72% (Figure 3C). The area method concordance interval
ranges from 22.79% to 7.72%. Thus, for MIQuant per heart infarct
size results the confidence interval of the predicted bias and
concordance limits are within acceptance limits (bias 62%,
concordance limits 67%) for both midline length- and area-
measurements, which show that the performance of MIQuant is
equivalent to the manual infarct size calculation.
Although the differences between MIQuant and manual
measurements are scattered around the bias with no obvious
pattern, the association between the two variables was investigated
using the Pearson Product-moment-correlation coefficient. Small
and non-statistically significant correlations were found for both
midline length (r=0.149; p=0.531) and area (r=20.315;
p=0.176) approaches, consequently discrepancies between the
manual and semi-automated quantification are independent of the
sample infarction size.
Validation of MIQuant by non-trained volunteer-users
To address whether previous experience with the MIQuant
application and knowledge on infarct size calculation are strict
requirements for the correct software usage, a comparison was
established between MIQuant results obtained by users with distinct
proficiency. Five hearts were independently analyzed by four
competent users (experts), i.e. investigators with extensive training
on MI size quantification either manually or using MIQuant, and
by volunteer-users with no previous experience on MI size
Table 1. Repeatability analysis of the manual and MIQuant results by repeated measures one-way ANOVA.
MI size (%) Midline length measurement
1 Area measurement
2
Measurement 1 Measurement 2 Measurement 3 Measurement 1 Measurement 2 Measurement 3
Manual
a 44.24613.01 44.84612.62 45.03612.82 31.2369.60 32.5169.29 31,9269.25
MIQuant
b 44.66613.26 44.58613.00 45.61613.01 34.0268.71 34.0068.16 35,0468.72
Values area mean 6 STDEV; n=20;
1, a Per LV: Wilks’Lambda=0.818, F(2, 18)=2.0001, p=0.164, multivariate partial eta squared=0.18; Per section:
Wilks’Lambda=0.990, F(2, 234)=2.0001, p=0.140, multivariate partial eta squared=0.322;
1, b Per LV: Wilks’Lambda=0.757, F(2, 18)=2.892, p=0.081, multivariate
partial eta squared=0.24; Per section: Wilks’Lambda=0.977, F(2, 234)=2.734, p=0.067, multivariate partial eta squared=0.023;
2, a Per LV: Wilks’Lambda=0.848, F(2,
18)=1.617, p=0.226, multivariate partial eta squared=0.15; Per section: Wilks’Lambda=0.969, F(2, 234)=3.737, p=0.025, multivariate partial eta squared=0.031;
2, b
Per LV: Wilks’Lambda=0.827, F(2, 18)=1.886, p=0.180, multivariate partial eta squared=0.17; Per section: Wilks’Lambda=0.981, F(2, 234)=2.286, p=0.104,
multivariate partial eta squared=0.019.
doi:10.1371/journal.pone.0025045.t001
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provided. An independent-samples t-test was conducted and no
significant differences were observed on the midline length and
area measurements obtained by either experts or volunteers (Figure 4).
In addition, a two–way ANOVA analysis of variance was
conducted to explore the impact of the observer type (expert or
volunteer) and the heart sample on MIQuant infarct size
measurement, obtained by either midline length (ML) or area
Figure 3. Validation of MIQuant for infarct size assessment. (A) Infarct size scatter diagram and the Pearson coefficient demonstrated strong
association between manual and MIQuant results for area (right) and midline length (left) approaches. (B) Bland-Altman concordance analysis of the
manual and MIQuant infarct size measurements demonstrated acceptable limits of agreement between methods. Average values of the three
independent measures of infarct size per section (B) and per heart (C) were subject to the analysis. Differences between the infarct sizes retrieved by
each method (MIQuant-manual) are displayed in the y-axis and the mean infarct size values are plotted in the x-axis. The limits of agreement (-- ) and
bias (&&&) and respective 95% confidence intervals ([ ]) are shown.
doi:10.1371/journal.pone.0025045.g003
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observer type (ML p=0.267; A p=0.77), whereas the effect of the
heart sample was found to be statistically significant (p,0.05).
Time-efficiency of MIQuant infarct size quantification
The manual quantification of MI size is a time-consuming and
laborious endeavor, thus the simplification of this task is highly
desired and was a major drive for the development of MIQuant.
The time required for manual and MIQuant-assisted infarct size
calculation was compared (Figure 5). The latter was additionally
compared for experts and volunteer operators. Despite the required
definition of initial parameters by the user prior to MIQuant
segmentation, this method resulted on a significant overall 4.5-
and 3-fold decrease in the time period spent on the analysis when
performed by competent and volunteer users, respectively.
Discussion
In this study, the development and validation of MIQuant,a
simple and user-friendly software application that calculates the
infarct size on cardiac models of induced-ischemia, is reported. To
our best knowledge, MIQuant constitutes the first computer-assisted
tool to ease the arduous and time-consuming endeavor of manual
infarct size calculation by classical planimetry.
The view of the heart as a post-mitotic organ has been challenged
inrecentyears by reportsofcardiomyocyterenewal inhumans[24],





cells [26,27,28]. These findings, together with the fact that
cardiovascular diseases are a major cause of morbidity/mortality,
have encouraged the publication of studies on the evaluation of
cardio-regenerative potential of novel therapies. The latter are
commonly tested on rodent models of MI and the infarct size has
been regarded as a decisive parameter for the determination of the
success ofthetherapyunder test.Althoughhistological planimetryis
the gold standard for infarct size quantification, methodological
discrepancies are frequent across publications due to a general lack
of standardized protocols/methods. The most common methods
used to quantify infarct extension are either based on the infarcted
area or on the length of the infarction circumference. Both
methodologies show limitations related to the infarct size estimation
accuracyusing parameters that areaffected and distorted by cardiac
remodeling subsequent to MI [29]. Regarding MIQuant, we decided
to make available two methods for infarct quantification: the area-
based quantification first described by Michael [13] and the midline
length measurement that was extensively validated recently [10]. In
accordance with Takagawa’s [10] observations on manual infarct
size quantification, with MIQuant we obtained a statistically
significant compression of the area results when compared to the
midline-length method. Overall, obvious consistency was achieved
between manual and MIQuant infarct size quantification, which was
further illustrated by the excellent correlation between both and by
Bland-Altman analysis. Bland-Altman analysis indicated good
agreement free from systematic bias for midline-length MIQuant
infarct scores (0.2563.84). Regarding the area measurements,
although MIQuant overestimates infarct size by 1.21–3.27% as
Figure 4. MIQuant efficacy is not affected by user proficiency.
MIQuant infarct size values obtained by competent (experts) and non-
trained (volunteer) users were compared and the mean values are
displayed as graph bars. Independent-samples t-test showed no
significant differences between infarct scores calculated by the experts
vs. volunteers; furthermore, a two–way ANOVA demonstrated no
significant influence of the user on the obtained infarct size value.
doi:10.1371/journal.pone.0025045.g004
Figure 5. MIQuant improves the time-efficiency of infarct size
quantification. The time consumption of the infarct size determina-
tion per heart (mean value of 12 representative sections of the LV) was
compared between the manual and MIQuant approaches. The D
indicates the mean value of each group. **p,0.01.
doi:10.1371/journal.pone.0025045.g005
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this overestimation is negligible. Moreover, a random dispersion of
results around the predicted bias was observed, demonstrating that
MIQuant results are reliable independently of the size of infarction.
The repeatability and reproducibility of MIQuant results were also
confirmed by the use of three independent measures obtained by
four independent observers. Overall these results indicate that
MIQuant is a reliable alternative to the manual quantification of
infarct size.
Despite being a determinant factor for an accurate estimation of
the infarct size[10], the number of transverse sections used for
such analysis is extremely variable across studies. One of the
advantages of MIQuant over the classical manual quantification is
the 4.5 fold reduction on the time spent on the analysis, thus
improving time-efficiency and allowing the investigator to increase
the number of sections per analysis and consequently the accuracy
of results.
MIQuant is available as freeware for research use. The
widespread use of MIQuant will constitute by itself a major
improvement towards normalization of infarct size assessment by
restricting the methods to the area and midline length, by
standardizing the histological stain used and by restricting the
criteria for the identification of the infarcted region. Our results
also indicated a tendency, although not statistically significant, for
reduced inter-observer variability in MIQuant infarct size scores
when compared to manual analysis. This may well be underes-
timated given that the observers in this study were investigators
that received similar training on infarct size calculation. It is
therefore expected that the diversity of criteria on infarct
identification/calculation of observers with different backgrounds
will result in increased variability for the manual outcome. In
contrast, we demonstrated that MIQuant efficacy is independent of
previous training with the software and experience on MI size
calculation. An interesting experiment would be a comparative
analysis between MIQuant and manual quantification with experts
from different laboratories to therefore undoubtedly clarify
whether MIQuant contributes to the homogenization of infarct
size results. Our attempts to engage in this task experts with
previous published work on infarct size histological quantification,
met with little success and the intent was therefore aborted.
For the interpretation of this study several limitations should be
considered: firstly a single species (mouse) was used for the
validation of MIQuant, and secondly the only model of cardiac
induced-ischemia performed was the permanent LAD coronary
artery ligation. However, the pathophysiological and morpholog-
ical alterations following MI are similar in the rat and the mouse
[9,30,31], supporting the applicability of MIQuant for the
quantification of rat infarcts. The extension of MIQuant to other
infarction models, e.g. ischemia-reperfusion or the cryoinjury, is of
major interest. Hence, because the software recognizes the
infarction region by the collagen deposition, a hallmark of
established infarction, we are confident on the software applica-
bility to other models. Indeed, in hearts with non-transmural
infarction that very much resembles the reperfusion scenario,
MIQuant infarct scores were similar to manual quantification (data
not shown).
We conclude that MIQuant is a valid and easy-to-use software
application that assists on infarct size calculation. The widespread
use of MIQuant will contribute to the reduction of time spent on the
analysis and for the standardization of infarct size quantification
across studies and, therefore, to a more systematic evaluation of
the cardiac regenerative potential of newly developed therapies.
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